Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
At its Annual Meeting of Stockholders held on May25, 2017 (the
Annual Meeting), the stockholders of Dimension Therapeutics,
Inc., a Delaware corporation (the Company) voted on the following
matters, which are described in detail in the Companys Proxy
Statement filed with the U.S. Securities and Exchange Commission
on April14, 2017: (i)to elect one Class II director, namely
Dr.Michael Dybbs, Ph.D., to hold office until the 2020 annual
meeting of stockholders and until his successor is duly elected
and qualified, subject to his earlier resignation or removal
(Proposal 1) and (ii)to ratify the appointment of
PricewaterhouseCoopersLLP as the Companys independent registered
public accounting firm for the fiscal year ending December31,
2017 (Proposal 2).
The Companys stockholders approved the nominee recommended for
election in Proposal 1 at the Annual Meeting.
Stockholders voted for directors as follows:
|
Class II Director Nominee |
For | Abstain/Withheld | BrokerNon-Votes | |||||||||
|
Michael Dybbs, Ph.D. |
14,139,088 | 816,518 | 5,136,785 |
The Companys stockholders approved Proposal 2. The votes cast at
the Annual Meeting were as follows: 20,074,450 voted for, 16,449
shares voted against and 1,492 shares abstained from voting.
About Dimension Therapeutics, Inc. (NASDAQ:DMTX)
Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa. Dimension Therapeutics, Inc. (NASDAQ:DMTX) Recent Trading Information
Dimension Therapeutics, Inc. (NASDAQ:DMTX) closed its last trading session down -0.10 at 1.05 with 85,884 shares trading hands.
